The company is located in Nanjing, China, and is committed to building a world-class biopharmaceutical company, building an integrated pharmaceutical internationalization platform, and becoming a bridgehead for domestic companies to enter the international market. It has a mature R&D, quality, registration, and sales team in the US, and has grown into one of the most important high-end injectable suppliers in the US at the rate of more than a dozen ANDA approvals every year. The company is a pharmaceutical enterprise integrating R&D, production and sales of pharmaceuticals. It actively lays out the fields of chemicals and biopharmaceuticals, and has established a rich product pipeline covering cardiovascular, neurological, anesthetic, antitumor preparations, surgical aids, and other high-value-added sterile injections. The company's main products, fluvirizine injections, carboplatin injections, azacitidine injections, busulfan injections, bendamustine hydrochloride for injections, melphalan hydrochloride for injections, and fluorouracil injections, etc. are anti-tumor preparations. Company honors: Jiangsu Certified Enterprise Technology Center, Jiangsu Open Economy Advanced Enterprise, Nanjing Municipal Key Agricultural Commercialization Leading Enterprise, etc.
No Data
No Data